These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [Randomized study during a year of early combination of L-dopa/lisuride in Parkinson disease]. Vermersch P; Fondarai J; Petit H Therapie; 1991; 46(6):481-6. PubMed ID: 1819154 [TBL] [Abstract][Full Text] [Related]
4. A study on the effect and tolerance of lisuride on Parkinson's disease. Bayülkem K; Erişir K; Tuncel A; Bayülkem B Adv Neurol; 1996; 69():519-30. PubMed ID: 8615174 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of piribedil as early combination to levodopa in patients with stable Parkinson's disease: a 6-month, randomized, placebo-controlled study. Ziegler M; Castro-Caldas A; Del Signore S; Rascol O Mov Disord; 2003 Apr; 18(4):418-25. PubMed ID: 12671949 [TBL] [Abstract][Full Text] [Related]
7. Terguride: partial dopamine agonist in the treatment of Parkinson's disease. Brücke T; Danielczyk W; Simányi M; Sofic E; Riederer P Adv Neurol; 1987; 45():573-6. PubMed ID: 3825735 [TBL] [Abstract][Full Text] [Related]
8. Early combination of bromocriptine and levodopa in Parkinson's disease: a prospective randomized study of two parallel groups over a total follow-up period of 44 months including an initial 8-month double-blind stage. Giménez-Roldán S; Tolosa E; Burguera JA; Chacón J; Liaño H; Forcadell F Clin Neuropharmacol; 1997 Feb; 20(1):67-76. PubMed ID: 9037575 [TBL] [Abstract][Full Text] [Related]
9. Lisuride and bromocryptine in L-Dopa stable-responder parkinsonian patients: a comparative, double-blind evaluation of cardiopressor and neurochemical effects. Micieli G; Martignoni E; Cavallini A; Pacchetti C; Rossi F; Horowski R; Nappi G Funct Neurol; 1996; 11(6):317-25. PubMed ID: 9074912 [TBL] [Abstract][Full Text] [Related]
10. Bromocriptine and lisuride in Parkinson disease. Lieberman AN; Gopinathan G; Neophytides A; Leibowitz M; Walker R; Hiesiger E Ann Neurol; 1983 Jan; 13(1):44-7. PubMed ID: 6830164 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of piribedil in early combination with L-dopa in the treatment of Parkinson's disease: a 6-month open study. Suwantamee J; Nidhinandana S; Srisuwananukorn S; Laptikultham S; Pisarnpong A; Chankrachang S; Bundhukul A J Med Assoc Thai; 2004 Nov; 87(11):1293-300. PubMed ID: 15825702 [TBL] [Abstract][Full Text] [Related]
12. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat. Henry B; Crossman AR; Brotchie JM Exp Neurol; 1999 Feb; 155(2):204-20. PubMed ID: 10072296 [TBL] [Abstract][Full Text] [Related]
13. Comparison between L-dopa and lisuride intravenous infusions: a clinical study. Ruggieri S; Stocchi F; Carta A; Bravi D; Bragoni M; Giorgi L; Agnoli A Mov Disord; 1988; 3(4):313-9. PubMed ID: 3211176 [TBL] [Abstract][Full Text] [Related]
14. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Holloway RG; Shoulson I; Fahn S; Kieburtz K; Lang A; Marek K; McDermott M; Seibyl J; Weiner W; Musch B; Kamp C; Welsh M; Shinaman A; Pahwa R; Barclay L; Hubble J; LeWitt P; Miyasaki J; Suchowersky O; Stacy M; Russell DS; Ford B; Hammerstad J; Riley D; Standaert D; Wooten F; Factor S; Jankovic J; Atassi F; Kurlan R; Panisset M; Rajput A; Rodnitzky R; Shults C; Petsinger G; Waters C; Pfeiffer R; Biglan K; Borchert L; Montgomery A; Sutherland L; Weeks C; DeAngelis M; Sime E; Wood S; Pantella C; Harrigan M; Fussell B; Dillon S; Alexander-Brown B; Rainey P; Tennis M; Rost-Ruffner E; Brown D; Evans S; Berry D; Hall J; Shirley T; Dobson J; Fontaine D; Pfeiffer B; Brocht A; Bennett S; Daigneault S; Hodgeman K; O'Connell C; Ross T; Richard K; Watts A; Arch Neurol; 2004 Jul; 61(7):1044-53. PubMed ID: 15262734 [TBL] [Abstract][Full Text] [Related]
15. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis. Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614 [TBL] [Abstract][Full Text] [Related]
17. [Lisuride in the combination treatment of Parkinson disease]. Jellinger K Wien Med Wochenschr; 1987 Apr; 137(7-8):155-9. PubMed ID: 3111099 [TBL] [Abstract][Full Text] [Related]
18. [Tandospirone citrate, a selective 5-HT1A agonist, alleviates L-DOPA-induced dyskinesia in patients with Parkinson's disease]. Kannari K; Kurahashi K; Tomiyama M; Maeda T; Arai A; Baba M; Suda T; Matsunaga M No To Shinkei; 2002 Feb; 54(2):133-7. PubMed ID: 11889759 [TBL] [Abstract][Full Text] [Related]
19. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment]. Jost WH; Klasser M; Reichmann H Fortschr Neurol Psychiatr; 2008 Oct; 76(10):594-9. PubMed ID: 18833504 [TBL] [Abstract][Full Text] [Related]
20. Effects of methylphenidate on response to oral levodopa: a double-blind clinical trial. Nutt JG; Carter JH; Carlson NE Arch Neurol; 2007 Mar; 64(3):319-23. PubMed ID: 17353373 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]